Listen to Prof. Andrew Kellett at Dublin City University speak on “A Click Chemistry Approach to Developing Gene-Directed Therapies."
Prof. Andrew Kellett is an investigator in SSPC and has published extensively within this theme, including recent work in Nucleic Acids Research (2021 & 2022) and Angewandte Chemie (2022), established new industry funded collaborations with MSD Carlow and Nanotemper GmbH, and filed two patents in the area of gene-directed therapies.
Andrew received an IRC Laureate Consolidator award for ENACT: Gene Editing with Nucleic Acid Click Chemistry. The project seeks to develop a new type of gene technology that contains two components: an artificial chemical nuclease containing a reactive metal ion capable of damaging DNA, and targeting vectors called triplex forming oligonucleotides (TFOs) and peptide nucleic acids (PNAs) that can recognise specific cancer-causing genes. The hybrid technology will be tested against cancer causing genes that are present in aggressive human cancers, including triple negative breast cancer and glioblastoma multiforme.
The presentation outlines:
Gene Editing Technologies
Artificial Chemical Nucleases
Click Chemistry-Based Cheical Nucleases
Gene Editing with Click Chemistry
Enzymatic Synthesis
Click chemistry, as the name suggests, is a way of building molecules like snapping Lego blocks together. It takes two molecules to click, so researchers refer to each one as click partners.
#clickchemistry #pharmaceutical #geneediting #dna #cancerresearch #biopharma
Негізгі бет Prof. Andrew Kellett
Пікірлер